Induction Mortality in Acute Myeloid Leukemia: A 9 Year Retrospective Study from a Tertiary Care Centre in a Low-Middle Income Country Setting

INTRODUCTION: Literature on acute myeloid Leukemia (AML) from low and middle income countries (LMIC) like India indicate lower uptake of intensive treatment (29%) and higher induction mortality (25%) (Philip C, BJH 2015). This is attributable to delayed presentation, higher infection burden, multi-drug resistant organism (MDRO) infections, poor nutritional status, access to care, and high costs driven by ‘out-of-pocket expenditures’, among other reasons.